Pancreatic cancer is feeling the heat
Pancreatic adenocarcinoma (PDAC) is considered an immunologically ‘cold’ tumor that fails to attract or support effector T cells. Most PDACs are resistant to immune checkpoint blockade due to the complex signaling pathways that exist within its tumor microenvironment. Recent advances in genomic and...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/10/e010124.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850147805673291776 |
|---|---|
| author | Elizabeth M Jaffee Saumya Y Maru |
| author_facet | Elizabeth M Jaffee Saumya Y Maru |
| author_sort | Elizabeth M Jaffee |
| collection | DOAJ |
| description | Pancreatic adenocarcinoma (PDAC) is considered an immunologically ‘cold’ tumor that fails to attract or support effector T cells. Most PDACs are resistant to immune checkpoint blockade due to the complex signaling pathways that exist within its tumor microenvironment. Recent advances in genomic and proteomic technology advances are finally uncovering the complex inflammatory cellular and intercellular signals that require modulation and reprogramming. The goal is to ‘turn up the heat’ on PDACs with combination immunotherapies that incorporate T cell activating agents and immune modulatory agents, and successfully eradicate tumors. Here, we discuss progress and promising new research that is moving the field toward this goal. |
| format | Article |
| id | doaj-art-4d94e6de809b45988ff0766b321ecba5 |
| institution | OA Journals |
| issn | 2051-1426 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-4d94e6de809b45988ff0766b321ecba52025-08-20T02:27:27ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262024-10-01121010.1136/jitc-2024-010124Pancreatic cancer is feeling the heatElizabeth M Jaffee0Saumya Y Maru11Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA1 Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USAPancreatic adenocarcinoma (PDAC) is considered an immunologically ‘cold’ tumor that fails to attract or support effector T cells. Most PDACs are resistant to immune checkpoint blockade due to the complex signaling pathways that exist within its tumor microenvironment. Recent advances in genomic and proteomic technology advances are finally uncovering the complex inflammatory cellular and intercellular signals that require modulation and reprogramming. The goal is to ‘turn up the heat’ on PDACs with combination immunotherapies that incorporate T cell activating agents and immune modulatory agents, and successfully eradicate tumors. Here, we discuss progress and promising new research that is moving the field toward this goal.https://jitc.bmj.com/content/12/10/e010124.full |
| spellingShingle | Elizabeth M Jaffee Saumya Y Maru Pancreatic cancer is feeling the heat Journal for ImmunoTherapy of Cancer |
| title | Pancreatic cancer is feeling the heat |
| title_full | Pancreatic cancer is feeling the heat |
| title_fullStr | Pancreatic cancer is feeling the heat |
| title_full_unstemmed | Pancreatic cancer is feeling the heat |
| title_short | Pancreatic cancer is feeling the heat |
| title_sort | pancreatic cancer is feeling the heat |
| url | https://jitc.bmj.com/content/12/10/e010124.full |
| work_keys_str_mv | AT elizabethmjaffee pancreaticcancerisfeelingtheheat AT saumyaymaru pancreaticcancerisfeelingtheheat |